Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Mar 11 2016

Full Issue

A Kayak.com For Drug Trial Sign-Ups?

An entrepreneur is taking a page from the travel industry with a new tool he thinks could tackle a long-standing inefficiency that's hobbled the pharmaceutical industry for years -- matching scientists to patients with the disease.

Bloomberg: Drug Tests Take Cue From Travel Site To Fix Industry Headache

Pablo Graiver aims to make signing up for a drug study as easy as booking a flight on the Web. The 47-year-old Argentinian entrepreneur, a former executive at the airfare search engine kayak.com, has designed a new tool that draws from the travel industry to match scientists looking to test experimental medicines with patients suffering from more than a dozen diseases. It pools information patients previously had to piece together from Google searches, doctors and a complicated government-run website. (Kitamura, 3/10)

In other pharmaceutical news, Valeant's CEO says there's no other shoe that's going to drop —

Bloomberg: Valeant CEO Says No More Surprises, In Meeting With Top Execs

Days after his surprise return from medical leave, Valeant Pharmaceuticals International Inc. Chief Executive Officer Michael Pearson gathered his senior managers at the company’s New Jersey offices to deliver a message: the drugmaker’s businesses were still mostly doing well, and Valeant was not going to go bankrupt. (Langreth, 3/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF